CompletedPhase 1NCT02840487
Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
Studying Zika virus disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Martin R Gaudinski, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- VRC-ZKADNA085-00-VP(biological)
- Enrollment
- 80 target
- Eligibility
- 18-35 years · All sexes
- Timeline
- 2016 – 2019
Study locations (3)
- Hope Clinic - Emory Vaccine Ctr, Decatur, Georgia, United States
- University of Maryland Ctr. for Vaccine Development, Baltimore, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02840487 on ClinicalTrials.govOther trials for Zika virus disease
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT04398901Neurodevelopmental Outcomes in ZIKV-Exposed ChildrenChildren's National Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03037164INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsCerus Corporation
- RECRUITINGNCT01386424Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsNational Institute of Allergy and Infectious Diseases (NIAID)